Oxygen Biotherapeutics, Inc. (OXBO) Release: University of Glasgow Study Demonstrates the Ability of Oxycyte® to Supply Oxygen to Critical Penumbral Tissue in Acute Ischemic Stroke  
8/21/2012 9:57:06 AM

MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT) announced today that recent research conducted by its partner, Aurum Biosciences (“Aurum”), Glasgow, Scotland, has shown that Oxycyte®, OBI’s proprietary perfluorocarbon-based intravenous emulsion, improves imaging of the penumbra following acute ischemic stroke in a rat model. The penumbra is the region of the brain where blood supply is inadequate to support normal brain function but sufficient to maintain tissue viability for a limited period of time following stroke. It represents potentially salvageable tissue which, if the oxygen supply can be restored, could lead to improved functional outcomes for stroke patients.